Member Info for PM2022

That can be said about any listed company so nothing new. Mark has invested heavily so clearly sees potential.

The fact that brokers took fees as shares indicates confidence that they believe they will get a decent return. You don't do that if you think the share will tank.

They also have warrants and therefore have the power to bring in buyers. Expecting significant news soon.

Not a hard sell for them at these prices and with 401 due to complete and CLX that has every chance of partnering in 2026 and hitting a market cap well over 10 million.

Two occasions with old management but for the first time we have a CEO that is heavily invested with warrants as well so we can forget about that.

Or the constant attacks by those all the way down and the need to protect your investment.

We don't know what happened with 201 but what matters is the current situation with the new BOD.

Shame really Uncanny and Patern have left even before the placing given all the abuse. The abusers cannot accept a positive post it just shows it.

@Jinky- Not by June 2026 but i think Valirx can reasonably hit 0.50-1.00 range in the coming weeks/months. By the end of 2026 hopefully if it runs smoothly then yeah possibly it can be a 10/20 bag from here. The reasons are below:

@ Rebster- No one’s pumping anything. I am sharing a view as someone who is invested.

I’ve got better things to do than debate about Valirx but after constant attacks from a few non-invested people, I’m putting my own views out there too. After all if I/we don't post they all say we should post so who are you.

Note I have not posted for months but the attacks have continued daily with no intention to invest.

You are not invested and it appears you have not been invested well at least for a few years.

The view of the company not delivering in the past is not the basis for not delivering in the future as in drug development it takes time. Past failure has provided an opportunity at this price and is more to do with issues relating to the legacy asset 201, delays and drop in confidence in that.

Valirx is making progress and is reaching the appropriate milestones and although the share price is down I see a strong recovery at this valuation and at this point.

Risks remain as usual but we should be relatively stable in the coming months possibly with some very significant moves upwards.

Medium pre clinical deals between 2022-2024 were 47 million dollars plus milestones and CLX is a novel compound with strong science and progressing well with a de-risked strategy:

From Biopharma drive

Companies with more proven drug assets are prized commodities. Between 2022 and the first half of 2024, the median upfront cash and equity payments for companies with drugs in late-stage testing spiked from $75 million to $200 million, according to J.P. Morgan. Over the same timeframe, the median upfront payouts to preclinical biotechs fell from $75 million to $47 million.

CLX: https://valirx.com/announcements/7133075

We also have a signed deal for VAL 401 which is 16 million plus milestones with 6 million near term milestones awaiting confirmation of funding once this is done this can move.

For a market cap of just over a million and low cash burn of around 1.5 million for a biotech and CLX001 progressing towards later stage pre-clinical and deal stage then we should hopefully see a strong move upwards in 2026.

Limited rIsks remain but on balance enough potential and a tiny market cap and approaching key milestones that should see this move up a fair amount. Just my view.

Try telling that to the CEO who purchased a large amount.

We will see. We can always bail out come May or June 2026 but for what it is worth I think this could be a decent 10 bagger as CLX001 edges to deal status in 2026. 401 update we should get at some point as well and numerous value added news. At this market cap I am happy to wait and see.

Yeah placing was disappointing but this very likely can get to a few pennies still so a good buy and hold imo provided that CLX continues to progress well. For now no fear of placing so a good few months to ride this out and see where we are.

Or a potential deal on the horizon in 2026 whether that be 10,20,30,40,50 million upfront with milestones in the 100s of millions.

Also a deal lined up for 401. This is a biotech therefore the goal is to ultimately get a deal.

The market cap of just over a million likely does not even cover the biobank.

Approx 1.5 million a year for a biotech with valuable products seems the best around.

Don't forget you invested in 4D losing over 1 million a week plus additional debt. You also invested in NYCT, HE1, GDR, INSP all tanked and a few others.

Don't get the agenda of constant posting if not invested. Clearly you are desperate to get some shares for someone somehow.

I don't think anyone will be selling based on your posts. DYOR.

Mark purchased another large amount.

Peel Hunt owned 9.5% around the 0.65p mark and have now doubled up and purchased more from what I can see.

Need I say anymore. The issue with Valirx is that it is poorly understood by the retail market but If Mark is smart he would get one or two institutional investors buying in the open market with a few decent outcomes on the way.

For as much as this has gone down it also presents an opportunity. With CLX progressing well and 401 deal I think Valirx should be above 10 million and cash burn remains well controlled for a biotech. With further news at some stage I would think this will reverse strongly.

So you want investors to sell so that your client buys below the placing price.

I'll worry about Valirx in June 2026 but I suspect by then we will be closer to 1p.

The previous investment involving 201 was a strategic failure by signing an exclusivity agreement with one party who were not able to raise the money for whatever reason. The DD should have been done by BOD back then but they are no longer leading Valirx so not relevant to the current situation.

NOW CLX is a different proposition. What I am saying is that CLX should progress in the coming months with key updates therefore driving the price up. Also 401 should bring material value. You don't sign a licensing deal with no clear plans so this should be in place.

They are addressing formulation and delivery using partnership deals and the lead formulation has already shown positive results from what i remember. Once ready the last stage should be very quick the point of these studies is to de-risk and speed up the final process which can be done very quickly if outcomes to these partnership deals are positive.

We are looking at the second half of 2026 for IND filing therefore the deal stage. They can secure one before that but likely for a lower amount.

We can see when we get the next updates what the plans are.

Valirx annual cash burn per month is £155k.

Please refer to RNS dated 29 September 2024 to work out your sums.

Raising a total of £902,000 gives a runway of 6 months add in R and D refund and a slightly measured cash burn and perhaps some revenue= 7 months.

It is worth noting from the RNS on 1 Sept 2025 that they are considering further non-dilutive funding for Cytolytik. This should hopefully reduce some of the costs.

As for the recent placing it is disappointing no doubt but even with the warrants issued I think this will be around the lowest price ever for Valirx and this will head back to 2-4p range in the next 12 months or slightly longer when getting closer to deal stage. Here is the reasoning:

CLX001- Key agreement Altus agreement for 12 months In Jan 2025 which allows them to test different formulations for delivery. I think we are coming to a conclusion and the outcome given Mark's investment could be positive and a significant milestone.

VAL301- Valirx get 6 million near term payments from Ambrose and a total of 16 million plus royalties and have already been awarded shares for signing the licensing agreement. When funds are raised shortly the market will realise the value of these shares.

As for funding and shortfall. Yes, it is possible they may need more in late 2026 for a small amount but It is likely to be directly through an institutional investor. We know the average deal size is about £30 million plus huge milestone payments so if a bit more funding was needed and the last time before deal stage it will likely be at a good price even a premium by then. I don't think Mark will have an issue getting this so I can't see him coming back to the retail market. The institutional investor will almost certainly hold until the deal is completed and by then it would not matter much.

Therefore despite the recent disappointment I see this being close to the lowest price for Valirx and if it gets to the deal stage as expected it could well hit 3/4p or higher. With Mark's investment I think he is confident. For what it is worth I will be holding.

Worst case they can sell the company and have over 7 months therefore plenty of time, despite claims CLX is worthless we all know that is nonsense as similar compounds at this stage are subjectively worth well over 10 million plus the 401 deal carries significant value so we would be looking at a price of 10 million plus even on the cheap imo.

At this market cap although it carries some risk I think the potential return is significant so therefore a good buy.

Oh also the warrants at 0.5p. It will not take much to activate these how low the market cap is therefore maybe further funding will not be needed.

I think we will get more news on 401, CLX and an SPV and some contracts signed. Like Mark said the target is to get the warrants in play. Any decent news and we can gap up again to 1p and above. Many missed out on the last rise but another one is due soon imo. Porky was telling everyone 0% the deal will get signed.

If the worst happened then at this market cap not expecting any large discounts, maybe a few warrants not sure. More likely we can double from here in the next few weeks.

Like I said I think we can get to a 5/10 million market cap at some point in the next few weeks so a long way to go.

So I asked chat GTP how much an IND drug should be worth: Here is the answer 20-30 million for oncology. A strong buy at this market cap imo:

As far as I know that is the target for this year plus we got the 401 deal. Valirx could be worth more than 10 million by year end.

What does “indication stage in preclinical” mean?

This typically means:

A specific disease or condition (indication) has been chosen.

The drug is still in preclinical development (i.e., not yet tested in humans).

Some proof-of-concept in vitro/in vivo data may exist.

There is no IND (Investigational New Drug) application filed yet.

💵 How much is a drug worth at this stage?

Valuation is usually determined by:

Stage of development (earlier = more risk = lower value).

Size of the potential market.

Competitive landscape.

IP position.

Preclinical data strength.

⚖️ Typical Valuation Range (as of recent industry norms):

$2 million to $10 million: for assets with a clear target and decent preclinical data.

Up to $20–30 million: if the asset targets a large market (e.g., oncology, CNS) and has strong preclinical efficacy/safety data.

< $1 million or option deals: if it’s early or unproven (e.g., hit-to-lead stage or little differentiation).

🧠 Note: These are “upfront” or “asset value” numbers, not total deal value including milestones/royalties.

The initial £6 million milestones are payable in cash or the equivalent value.

That is not bad given our current market cap. More later including royalty payments. Like all listed companies with deals it is the potential that counts and to some degree gets priced in. CLX remains the main asset and not priced in.

Plenty of value on offer with so much news likely to come. Decent chance we hit 1.50-2.00 p range and even if cash was needed I don't think it will be a large discount. The deal changes everything. All those reinvesting will need to protect the warrants they have if the price was lower and also the CEO is also invested heavily. Therefore a great buy at this price given the market cap imo.

All these hours you put in deramping at 0.40p and now we are almost double.

What you say does not matter. More news will come shortly and like Mark said the target is to get some warrant cash so they are looking at a target of 1.50-2.00p.

More news on 401, CLX, SPV and some contracts likely. If a placing does happen in a few months I would expect a minimal discount given the potential value of 401 and CLX. Maybe 10-20% from above 1.00p but we would easily hit 2.00p if warrants come into play and further cash comes in.

Sadly Porky missed out on the 0.20 price prediction. More likely we hit 2.2p with warrants executed.

Future secured and no big discounts. The only way is up.

Not true at all. My old average was also in the single digits. You don't know the level of top ups relative to how much I have or had so best not speculate.

Foolish WCB, keep watching and waiting. This is what happens, a gap up and you missed out. Soon we will be 1p plus and up and up.

Fools like you will always sit and wait and watch this go up.

As I said earlier I reinvested at the placing price so in profit.

Chances of it getting to market is fairly high given the stage this is at giving investors a high chance of very significant returns. It is the actual revenue that 401 will generate that will matter to them. So if we say 50% chance of success to get 20/30 times the return then it is very investible. Therefore funding is no issues and 401 being signed was always likely.

SP should rerate and we are also due a CLX update at some point with more news to come on other projects.

All about building momentum and looks like this is the start. Expecting second news on Ambrose as well shortly and perhaps a strong CLX update. 1.50-2.00 target in the next 2-4 weeks. Maybe even today who knows.